BUZZ-Tonix pain‑relief drug meets main goal in late‑stage study; shares fall

Reuters01-30
BUZZ-Tonix pain‑relief drug meets main goal in late‑stage study; shares fall

** Shares of drug developer Tonix Pharmaceuticals TNXP.O fall 1.6% to $17.93 premarket

** Co says its pain‑relief drug Tonmya met the main goal in a late‑stage study for Fibromyalgia, a chronic widespread pain condition

** Fibromyalgia causes long‑lasting body pain and poor sleep; co's Tonmya is taken under the tongue at bedtime - TNXP

** Co says the 14‑week study showed less pain, better sleep, and improvements in fatigue and daily function vs placebo

** TNXP cautions use in people with heart or thyroid issues, those on certain antidepressants, and pregnancy

** Co's Tonmya was approved by the FDA in August 2025 as the first new prescription treatment for this condition in more than 15 years

** Shares down ~53% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment